Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,334 across all filing types
Latest filing 2020-08-21 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi approved in Japan for SCLC
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 8089W' and is dated August 21, 2020. It announces a specific corporate event: the approval of the drug Imfinzi in Japan. This type of announcement, which is a material, time-sensitive update distributed via the Regulatory News Service (RNS) system, fits best under the general 'Regulatory Filings' category, as it is not a comprehensive financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder/director transaction. The presence of the RNS header strongly suggests this classification.
2020-08-21 English
IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE
Foreign Filer Report
2020-08-18 English
Imfinzi US Priority Review; four-week, fixed dose
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content details a specific regulatory action ('Imfinzi granted FDA Priority Review') and provides extensive background information on the drug, the disease indications (NSCLC and bladder cancer), and the company's broader pipeline. This format—a press release style announcement of a regulatory event or clinical update, distributed via RNS—is characteristic of a general regulatory filing or news release. Since it is not a full annual report (10-K), a quarterly report (IR), a proxy statement (DEF 14A), or a specific transaction report (like DIRS or POS), the most appropriate classification is the general regulatory announcement category, RNS.
2020-08-18 English
NYSE CERTIFICATION
Regulatory Filings
2020-08-12 English
FORM 8-A12B
Regulatory Filings
2020-08-06 English
FORM 6-K
Foreign Filer Report
2020-08-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.